Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22266312 | 0.97 | PPARA (0.35) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL22266387 | 0.94 | MAPT (0.34) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL22266359 | 0.94 | TSHR (0.37) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL6391920 | 0.86 | PPARA (0.40) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL9666337 | 0.84 | PPARA (0.42) | PPARAMAPTRECQLEPHX2SMN1; SMN2 | |
| SCHEMBL20232094 | 0.84 | NMT1 (0.35) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL20232108 | 0.84 | NMT1 (0.35) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL20234356 | 0.84 | NMT1 (0.35) | PPARACHRNB2CHRNA4MAPTRECQL | |
| SCHEMBL20322493 | 0.83 | MAPT (0.33) | PPARAMAPTRECQLNMT1PDE10A | |
| SCHEMBL22224155 | 0.81 | PPARA (0.40) | PPARAMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | PPARA 4259/4885CHRNB2 3283/4885CHRNA4 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.